ResMed Shares Face Pressure Following Goldman Sachs Downgrade
03.12.2025 - 13:43:05Resmed US7611521078
ResMed’s stock is experiencing notable selling pressure in today’s trading session. This movement follows a significant shift in sentiment from a major Wall Street institution, coupled with concerning signals from company insiders and technical charts.
The primary catalyst for the current reassessment of ResMed is an adjustment by Goldman Sachs. The investment bank has removed the healthcare company’s shares from its prestigious “Conviction List.” This list is reserved for equities in which the firm maintains its highest conviction regarding future performance. The removal represents a marked decline in confidence concerning ResMed’s near-term price trajectory and often serves as a notable indicator for other institutional market participants.
